Phibro Animal Health | PAHC - 销售和管理费用

金融业

USD

USD 1.41B

现金及等价物

USD 55.49M

USD 240.42M

USD 862.19M

USD 282.37M

USD 474.17M

股息收益率

1.29

USD 54.99M

USD 68.1M

1.92K

EPS每股收益

USD 0.78

股本和储备

USD 332.36M

USD 133.5M

债务利息支出

USD 11.91M

USD 0.08

USD 603.6M

USD 2.34B

USD 27.46M

USD 332.36M

USD 54.99M

普通股股本

USD 40.48M

13.82

USD 38.63M

USD 373.91M

销售和管理费用

USD 78.32M

USD 517.35M

贸易债权人

USD 133.3M

应收帐款人

USD 215.87M

	销售和管理费用	更改		日
Align Technology	USD 441.68M		23.88M	2025-12
ANI Pharmaceuticals	USD 82.79M		6.13M	2025-12
Assertio Holdings	USD 16.73M		1.66M	2024-09
Aurora Cannabis	CAD 40.62M		1.17M	2025-12
Bristol-Myers Squibb	USD 2.18B		392M	2025-12
Canopy Growth	CAD 28.9M		636K	2025-12
Corcept Therapeutics	USD 114.74M		7.77M	2025-12
Eli Lilly	USD 3.13B		391.3M	2025-12
Henry Schein	USD 808M		48M	2025-12
Idexx Laboratories	USD 275.68M		10.58M	2025-12
Knight Therapeutics	CAD 35.45M		4.43M	2025-12
Merck	USD 2.85B		215M	2025-12
Nektar Therapeutics	USD 10.17M		10.17M	2025-12
Pacira	USD 91.87M		70K	2025-12
Phibro Animal Health	USD 78.32M		10.24M	2025-12
Prestige Brands	USD 29.67M		1.64M	2025-12
Supernus Pharmaceuticals	USD 122.39M		57.29M	2025-12
Zoetis	USD 619M		40M	2025-12